摘要
目的 观察前列地尔 (PGE1)对非瓣膜病心力衰竭 (CHF)患者的临床疗效。方法 随机将 39例住院非瓣膜病CHF患者分为两组 ,A组 2 0例 ,在CHF常规治疗基础上加用PGE14 0 μg/d ,共 14d。B组 19例为CHF常规治疗组。观察治疗前后各组及组间心功能变化、血压、心率及超声心动图改变。结果 各组治疗后较治疗前心功能均有不同程度改善 ,但PGE1组更为明显 ,差异有显著意义。PGE1组治疗后较治疗前血压有明显下降 ,但心率变化不显著。结论 前列地尔对非瓣膜病心力衰竭有明显疗效。
Objective To study the effects of lipoprostaglandin E 1(PGE 1) on patients with congestive heart failure(CHF) from non-valve heart disease.Methods 41 patients with CHF from non-valve heart disease were randomly divided into a treatment group(n=21,Lipo PGE 1 120 μg/day,iv,based on convention therapy) and a control group(n=20,convention therapy).Blood pressure,heart rate and echocardiography were measured before and after treatment.Results Improvement of echocardiography were significant in both groups,but it was more significant in treatment group(statistically).Blood pressure was reduced obviously,but heart rate had no change.The adverse effects of Lipo PGE 1 were less.Conclusion Lipo PGE 1 has remarkable effects on CHF from non-valve heart disease.
